Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study

References

• Tzonova D, Larrosa O, Calvo E, et al. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis–Ekbom disease). Sleep Med 2012;13:151-5
   PubMed Web of Science ®Google Scholar
• Rye DB, Trotti LM. Restless legs syndrome and periodic leg movements of sleep. Neurologic Clinics 2012;30:1137-66
   PubMed Web of Science ®Google Scholar
• Ferri R, Manconi M, Plazzi G, et al. Leg movements during wakefulness in restless legs syndrome: time structure and relationships with periodic leg movements during sleep. Sleep Med 2012;13:529-35
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Kohnen R, Boothby L, et al. Validation of the multiple suggested immobilization test: a test for the assessment of severity of restless legs syndrome (Willis–Ekbom disease). Sleep 2013;36:1101-9
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Boucher S, Nicolas A, et al. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord 1998;13:324-9
   PubMed Web of Science ®Google Scholar
• Michaud M, Lavigne G, Desautels A, et al. Effects of immobility on sensory and motor symptoms of restless legs syndrome. Mov Disord 2002;17:112-15
   PubMed Web of Science ®Google Scholar
• Michaud M, Paquet J, Lavigne G, et al. Sleep laboratory diagnosis of restless legs syndrome. Eur Neurol 2002;48:108-13
   PubMed Web of Science ®Google Scholar
• Michaud M, Dumont M, Paquet J, et al. Circadian variation of the effects of immobility on symptoms of restless legs syndrome. Sleep 2005;28:843-6
   PubMed Web of Science ®Google Scholar
• Hening WA, Walters AS, Wagner M, et al. Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep 1999;22:901-12
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Therapeut 2012;34:966-78
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19
   PubMed Web of Science ®Google Scholar
• Benes H, Kohnen R. Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med 2009;10:515-23
   PubMed Web of Science ®Google Scholar
• Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008;131:902-17
   PubMed Web of Science ®Google Scholar
• Kohnen R, García-Borreguero D, Allen R, et al. Transdermal rotigotine improved daytime functioning and daytime symptoms in patients with idiopathic restless legs syndrome. Mov Disord 2011;26:S362-3
   PubMed Web of Science ®Google Scholar
• Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10:710-20
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Berg D, Hofmann WE, et al. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Sleep Med 2013;14:475-81
   PubMed Web of Science ®Google Scholar
• de la Fuente-Fernández R. The powerful pre-treatment effect: placebo responses in restless legs syndrome trials. Eur J Neurol 2012;19:1305-10
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hossain MM, Gordon MF, Reess J. Predictors of placebo response in restless legs syndrome studies. Neurology 2013;81:193-4
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009;19:34-40
   PubMed Web of Science ®Google Scholar
• Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010;67:857-65
   PubMed Web of Science ®Google Scholar
• Allen R, Oertel W, Walters A, et al. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire. Sleep Med 2013;14:1375-80
   PubMed Web of Science ®Google Scholar